256 related articles for article (PubMed ID: 24891274)
1. A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia.
Burke MJ; Lamba JK; Pounds S; Cao X; Ghodke-Puranik Y; Lindgren BR; Weigel BJ; Verneris MR; Miller JS
Am J Hematol; 2014 Sep; 89(9):889-95. PubMed ID: 24891274
[TBL] [Abstract][Full Text] [Related]
2. Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study.
Burke MJ; Kostadinov R; Sposto R; Gore L; Kelley SM; Rabik C; Trepel JB; Lee MJ; Yuno A; Lee S; Bhojwani D; Jeha S; Chang BH; Sulis ML; Hermiston ML; Gaynon P; Huynh V; Verma A; Gardner R; Heym KM; Dennis RM; Ziegler DS; Laetsch TW; Oesterheld JE; Dubois SG; Pollard JA; Glade-Bender J; Cooper TM; Kaplan JA; Farooqi MS; Yoo B; Guest E; Wayne AS; Brown PA
Clin Cancer Res; 2020 May; 26(10):2297-2307. PubMed ID: 31969338
[TBL] [Abstract][Full Text] [Related]
3. Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia.
Benton CB; Thomas DA; Yang H; Ravandi F; Rytting M; O'Brien S; Franklin AR; Borthakur G; Dara S; Kwari M; Pierce SR; Jabbour E; Kantarjian H; Garcia-Manero G
Br J Haematol; 2014 Nov; 167(3):356-65. PubMed ID: 25066676
[TBL] [Abstract][Full Text] [Related]
4. A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome.
Kirschbaum M; Gojo I; Goldberg SL; Bredeson C; Kujawski LA; Yang A; Marks P; Frankel P; Sun X; Tosolini A; Eid JE; Lubiniecki GM; Issa JP
Br J Haematol; 2014 Oct; 167(2):185-93. PubMed ID: 25040094
[TBL] [Abstract][Full Text] [Related]
5. A phase I trial of two sequence-specific schedules of decitabine and vorinostat in patients with acute myeloid leukemia.
How J; Minden MD; Brian L; Chen EX; Brandwein J; Schuh AC; Schimmer AD; Gupta V; Webster S; Degelder T; Haines P; Stayner LA; McGill S; Wang L; Piekarz R; Wong T; Siu LL; Espinoza-Delgado I; Holleran JL; Egorin MJ; Yee KW
Leuk Lymphoma; 2015; 56(10):2793-802. PubMed ID: 25682963
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia.
Bhatla T; Wang J; Morrison DJ; Raetz EA; Burke MJ; Brown P; Carroll WL
Blood; 2012 May; 119(22):5201-10. PubMed ID: 22496163
[TBL] [Abstract][Full Text] [Related]
7. Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide).
Xia C; Leon-Ferre R; Laux D; Deutsch J; Smith BJ; Frees M; Milhem M
Cancer Chemother Pharmacol; 2014 Oct; 74(4):691-7. PubMed ID: 25062770
[TBL] [Abstract][Full Text] [Related]
8. Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study.
Walter RB; Medeiros BC; Gardner KM; Orlowski KF; Gallegos L; Scott BL; Hendrie PC; Estey EH
Haematologica; 2014 Jan; 99(1):54-9. PubMed ID: 24142996
[TBL] [Abstract][Full Text] [Related]
9. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
[TBL] [Abstract][Full Text] [Related]
10. Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma.
Nieto Y; Valdez BC; Thall PF; Jones RB; Wei W; Myers A; Hosing C; Ahmed S; Popat U; Shpall EJ; Qazilbash M; Gulbis A; Anderlini P; Shah N; Bashir Q; Alousi A; Oki Y; Fanale M; Dabaja B; Pinnix C; Champlin R; Andersson BS
Cancer; 2016 Sep; 122(17):2680-8. PubMed ID: 27203405
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas.
Stathis A; Hotte SJ; Chen EX; Hirte HW; Oza AM; Moretto P; Webster S; Laughlin A; Stayner LA; McGill S; Wang L; Zhang WJ; Espinoza-Delgado I; Holleran JL; Egorin MJ; Siu LL
Clin Cancer Res; 2011 Mar; 17(6):1582-90. PubMed ID: 21278245
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia.
Song LX; Xu L; Li X; Chang CK; Zhang Y; Wu LY; He Q; Zhang QX; Li X
Ann Hematol; 2012 Dec; 91(12):1879-86. PubMed ID: 22895556
[TBL] [Abstract][Full Text] [Related]
13. Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively.
Gao S; Li Z; Fu JH; Hu XH; Xu Y; Jin ZM; Tang XW; Han Y; Chen SN; Sun AN; Wu DP; Qiu HY
Asian Pac J Cancer Prev; 2015; 16(15):6627-32. PubMed ID: 26434886
[TBL] [Abstract][Full Text] [Related]
14. Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML.
Scandura JM; Roboz GJ; Moh M; Morawa E; Brenet F; Bose JR; Villegas L; Gergis US; Mayer SA; Ippoliti CM; Curcio TJ; Ritchie EK; Feldman EJ
Blood; 2011 Aug; 118(6):1472-80. PubMed ID: 21613261
[TBL] [Abstract][Full Text] [Related]
15. Decitabine prior to salvaged unrelated cord blood transplantation for refractory or relapsed childhood acute leukemia.
Zhou H; Zheng C; Zhu X; Tang B; Tong J; Zhang X; Zhang L; Liu H; Sun Z
Pediatr Transplant; 2016 Dec; 20(8):1117-1124. PubMed ID: 27620713
[TBL] [Abstract][Full Text] [Related]
16. Treatment of children with relapsed and refractory acute lymphoblastic leukemia with mitoxantrone, vincristine, pegaspargase, dexamethasone, and bortezomib.
August KJ; Guest EM; Lewing K; Hays JA; Gamis AS
Pediatr Blood Cancer; 2020 Mar; 67(3):e28062. PubMed ID: 31724803
[TBL] [Abstract][Full Text] [Related]
17. The combination of bortezomib with chemotherapy to treat relapsed/refractory acute lymphoblastic leukaemia of childhood.
Bertaina A; Vinti L; Strocchio L; Gaspari S; Caruso R; Algeri M; Coletti V; Gurnari C; Romano M; Cefalo MG; Girardi K; Trevisan V; Bertaina V; Merli P; Locatelli F
Br J Haematol; 2017 Feb; 176(4):629-636. PubMed ID: 28116786
[TBL] [Abstract][Full Text] [Related]
18. Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium.
Pommert L; Schafer ES; Malvar J; Gossai N; Florendo E; Pulakanti K; Heimbruch K; Stelloh C; Chi YY; Sposto R; Rao S; Huynh VT; Brown P; Chang BH; Colace SI; Hermiston ML; Heym K; Hutchinson RJ; Kaplan JA; Mody R; O'Brien TA; Place AE; Shaw PH; Ziegler DS; Wayne A; Bhojwani D; Burke MJ
Am J Hematol; 2022 May; 97(5):613-622. PubMed ID: 35180323
[TBL] [Abstract][Full Text] [Related]
19. A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML.
Gore L; Triche TJ; Farrar JE; Wai D; Legendre C; Gooden GC; Liang WS; Carpten J; Lee D; Alvaro F; Macy ME; Arndt C; Barnette P; Cooper T; Martin L; Narendran A; Pollard J; Meshinchi S; Boklan J; Arceci RJ; Salhia B
Clin Epigenetics; 2017; 9():108. PubMed ID: 29034009
[TBL] [Abstract][Full Text] [Related]
20. Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients.
Pera B; Tang T; Marullo R; Yang SN; Ahn H; Patel J; Elstrom R; Ruan J; Furman R; Leonard J; Cerchietti L; Martin P
Clin Epigenetics; 2016; 8():79. PubMed ID: 27453763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
